Fiche publication
Date publication
janvier 2020
Journal
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
Lien Pubmed
Résumé
ctDNA provided by liquid biopsy offers a promising alternative to tumor biopsy as it gives a non-invasive and «real-time» access to the cancer genome and reflects tumor intra and extra heterogeneity. ctDNA has shown growing clinical interest for cancer diagnosis, prognosis, theragnostics, therapeutic monitoring, and clonal evolution tracking. A major technical limit for ctDNA analysis from body fluids is the extremely low proportion of ctDNA compared to non-malignant cell-free DNA, underscoring the need for highly sensitive and specific detection techniques. The control of pre-analytical procedures appears essential for optimal ctDNA analysis and need to be standardized for clinical research applications. This chapter provides insights into major current technologies for ctDNA detection. Overall, PCR-based techniques are able to detect limited molecular alterations and have a high sensitivity suitable for monitoring purposes while NGS-based approaches are broad range molecular screening assays more specifically indicated for treatment selection. We briefly reviewed new technical innovations that are now available for ctDNA detection.
Mots clés
Cell-free DNA, Circulating tumor DNA, Liquid biopsy, Next-generation sequencing, Polymerase chain reaction
Référence
Recent Results Cancer Res.. 2020 ;215:181-211
